WAVE Life Sciences Ltd PRECISION-HD Trial Results and Business Update Call Transcript
Good afternoon, and welcome to the Wave Life Sciences investor conference call. (Operator Instructions) As a reminder, this call is being recorded and webcast.
I'll now turn the call over to Kate Rausch, Head of Investor Relations at Wave Life Sciences. Please go ahead.
Thank you, operator. Good afternoon, and thank you for joining us. With me here today is Dr. Paul Bolno, President and CEO of Wave Life Sciences; and Dr. Mike Panzara, Wave's Chief Medical Officer and Head of Therapeutics Discovery and Development.
This afternoon, we issued a news release announcing results from our PRECISION-HD1 and PRECISION-HD2 core and open-label extension trials. That release can be found in the Investors section of our website at www.wavelifesciences.com, along with a copy of the slides to accompany today's webcast, which will be posted following this call.
Before we begin, I would like to remind you that we'll be making
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
